Men at High Genetic Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT03805919 (https://clinicaltrials.gov/show/NCT03805919)

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

About the Study

The National Cancer Institute opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation.

View the study on ClinicalTrials.gov or contact Anna Couvillon, NP at: (240) 858-3148 or by email.

What the Study Entails

Screening MRI of the prostate every 2 years
Annual PSA blood test
Biopsy of the prostate if any MRIs are abnormal
No cost for study-related tests or procedures
No cost for travel
Clinical information will be shared with you and your doctor, if you choose
Genetic testing is not offered as part of the study

Study Lead Investigator

Fatima Karzai, MD, National Cancer Institute (NCI)

Study Site

The National Institutes of Health (NIH), Clinical Center
Bethesda, MD in the Washington, DC metro area
NIH can cover the cost of travel for participants

This Study is Open To:

Men, 30 to 75 years old without prostate cancer who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM) mutation.
Genetic testing is not offered.

This Study is Not Open To:

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.

Print